Sarepta Therapeutics, Inc. (SRPT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Sarepta Therapeutics reported revenue of $2.20B, up 15.6% from $1.90B the year before. Net income was -$713.4M (a -32.5% net margin), or -$7.13 per diluted share. Gross margin was 98.8% and operating margin was -31.8%. Operating activities generated -$205.5M of cash, leaving -$307.5M of free cash flow. At fiscal year end, Sarepta Therapeutics held $3.35B in total assets against $2.21B in total liabilities, including $801.3M of cash and equivalents.
Open the full interactive Sarepta Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Sarepta Therapeutics Key Stats
| Share Price | $16.51 |
|---|---|
| Market Cap | $1.74B |
| Revenue YoY Growth | +15.6% |
| 52-Week Range | $14.86 – $24.45 |
| Shares Outstanding | 105.4 million (basic, 2026 Q2) |
Sarepta Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $540.1M | $701.9M | $933.0M | $1.24B | $1.90B | $2.20B |
| Cost of Goods Sold | $1.10B | $1.16B | $1.47B | $1.51B | $1.68B | $2.90B |
| Gross Profit | -$564.2M | -$459.7M | -$536.2M | -$267.8M | $218.1M | $2.17B |
| Operating Income | -$564.2M | -$459.7M | -$536.2M | -$267.8M | $218.1M | -$699.8M |
| Pre-Tax Income | -$553.1M | -$418.9M | -$690.0M | -$520.1M | $260.8M | -$702.2M |
| Income Tax | $1.1M | -$168,000 | $13.5M | $15.9M | $25.5M | $11.2M |
| Net Income | -$554.1M | -$418.8M | -$703.5M | -$536.0M | $235.2M | -$713.4M |
| Diluted EPS | -$7.11 | -$5.15 | -$8.03 | -$5.80 | $2.34 | -$7.13 |
Sarepta Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $399.4M | $442.9M | $730.8M | $401.3M |
| Net Income | -$179.9M | -$282.8M | $331.0M | -$4.9M |
| Diluted EPS | -$1.80 | -$2.83 | $2.88 | -$0.05 |
Sarepta Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.50B | $2.12B | $966.8M | $428.4M | $1.10B | $801.3M |
| Current Assets | $2.49B | $2.60B | $2.56B | $2.58B | $3.07B | $2.54B |
| Total Assets | $2.98B | $3.15B | $3.13B | $3.26B | $3.96B | $3.35B |
| Current Liabilities | $416.0M | $452.7M | $619.6M | $653.7M | $731.7M | $1.10B |
| Total Long-Term Debt | $992.5M | $1.10B | $1.54B | $1.24B | $1.14B | $829.0M |
| Total Liabilities | $2.22B | $2.22B | $2.74B | $2.41B | $2.44B | $2.21B |
| Shareholders' Equity | $761.8M | $928.0M | $384.9M | $859.3M | $1.53B | $1.14B |
Sarepta Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $107.5M | -$443.2M | -$325.3M | -$501.0M | -$205.8M | -$205.5M |
| Cash From Investing | -$121.7M | $495.4M | -$1.05B | -$165.8M | $755.6M | $69.6M |
| Cash From Financing | $682.3M | $561.6M | $232.5M | $125.0M | $124.8M | -$168.3M |
| Free Cash Flow | $25.3M | -$481.7M | -$356.2M | -$577.1M | -$342.7M | -$307.5M |
Figures from Sarepta Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Sarepta Therapeutics financials page for every line item.
Sarepta Therapeutics Company Profile
| Ticker | SRPT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000873303 |
Frequently Asked Questions
What was Sarepta Therapeutics' revenue in fiscal 2025?
Sarepta Therapeutics (SRPT) reported revenue of $2.20B for fiscal 2025.
What is Sarepta Therapeutics' annual revenue history?
Sarepta Therapeutics' annual revenue by fiscal year: 2020: $540.1M; 2021: $701.9M; 2022: $933.0M; 2023: $1.24B; 2024: $1.90B; 2025: $2.20B.
What was Sarepta Therapeutics' net income in fiscal 2025?
Sarepta Therapeutics reported net income of -$713.4M for fiscal 2025.
What was Sarepta Therapeutics' earnings per share (EPS) in fiscal 2025?
Sarepta Therapeutics' diluted EPS was -$7.13 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Sarepta Therapeutics generate in fiscal 2025?
Sarepta Therapeutics generated -$307.5M of free cash flow in fiscal 2025.
What was Sarepta Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Sarepta Therapeutics reported revenue of $401.3M.
How much debt does Sarepta Therapeutics have?
Sarepta Therapeutics reported $829.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Sarepta Therapeutics are outstanding?
Sarepta Therapeutics reported a weighted average of 105.4 million basic shares outstanding in 2026 Q2.
What is Sarepta Therapeutics' market cap?
Based on its latest closing price, Sarepta Therapeutics (SRPT) has a market capitalization of about $1.74B.
When does Sarepta Therapeutics' fiscal year end?
Sarepta Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Sarepta Therapeutics headquartered?
Sarepta Therapeutics lists its business address in Cambridge, Massachusetts in its SEC filings.